Kensey Nash TriActiv
This article was originally published in The Gray Sheet
Executive Summary
Firm predicts delay in distal protection system launch as it enters into another question-and-response tango with FDA. The firm replied to a previous round of inquiries last November. Kensey Nash plans to have 10 TriActiv sales reps on hand upon 510(k) clearance in "the near term." The device will compete with Boston Scientific's FilterWire and Medtronic's GuardWire in the $100 mil. SVG embolic protection market (1"The Gray Sheet" Jan. 24, 2005, p. 24)...
You may also be interested in...
Kensey Nash Touts Prospects For TriActiv Embolic Protection Device
Kensey Nash believes the embolic protection market for saphenous vein graft procedures will double to more than $200 mil. in the next few years as physicians use distal protection to diminish their exposure to litigation
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.